茚達特羅

化合物

茚達特羅INN:indacaterol)是諾華公司開發的超長效β-腎上腺素受體激動劑英語Long-acting beta-adrenoceptor agonist[5]與相關藥物福莫特羅沙美特羅不同,它每天只需服用一次。[6]該藥物僅被許可用於治療慢性阻塞性肺病(迄今為止缺乏哮喘患者的長期數據)。它可通過乾粉吸入器英語Dry-powder inhaler氣霧劑形式輸送。

茚達特羅
臨床資料
商品名英語Drug nomenclatureOnbrez Breezhaler、Arcapta Neohaler
AHFS/Drugs.com國際藥品名稱
核准狀況
懷孕分級
給藥途徑吸入
ATC碼
法律規範狀態
法律規範
識別資訊
  • 5-[2-[(5,6-Diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one
CAS號312753-06-3  checkY
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
ECHA InfoCard100.218.577 編輯維基數據鏈接
化學資訊
化學式C24H28N2O3
摩爾質量392.50 g·mol−1
3D模型(JSmol英語JSmol
  • O=C4/C=C\c1c(c(O)ccc1[C@@H](O)CNC3Cc2cc(c(cc2C3)CC)CC)N4
  • InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1 checkY
  • Key:QZZUEBNBZAPZLX-QFIPXVFZSA-N checkY

醫療用途

考科藍合作組織的一項綜述發現,茚達特羅在改善慢性阻塞性肺病患者的肺功能方面效果至少與每日兩次長效β2受體激動劑相當。[7]

歷史

它於2009年11月30日獲得歐洲藥品管理局批准,商品名為Onbrez Breezhaler,[8]。它也於2011年7月1日獲得美國食品和藥物管理局批准,商品名為Arcapta Neohaler。[9][10]2016年,諾華將Arcapta Neohaler的美國商業權授權給Sunovion英語Sunovion製藥。[11]

參考資料

  1. ^ Arcapta Neohaler (indacaterol) inhalation powder Initial U.S. Approval: 2011. DailyMed. 1 April 2020 [14 June 2021]. (原始內容存檔於2021-06-15). 
  2. ^ Onbrez Breezhaler EPAR. European Medicines Agency (EMA). 17 September 2018 [20 January 2021]. (原始內容存檔於2021-01-28). 
  3. ^ Oslif Breezhaler EPAR. European Medicines Agency (EMA). 17 September 2018 [20 January 2021]. (原始內容存檔於2021-01-28). 
  4. ^ Hirobriz Breezhaler EPAR. European Medicines Agency (EMA). 17 September 2018 [20 January 2021]. (原始內容存檔於2021-01-28). 
  5. ^ Cazzola M, Matera MG, Lötvall J. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs. July 2005, 14 (7): 775–83. PMID 16022567. S2CID 11930383. doi:10.1517/13543784.14.7.775. 
  6. ^ Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma. Eur. Respir. J. May 2007, 29 (5): 871–8. PMID 17251236. doi:10.1183/09031936.00060006 . 
  7. ^ Geake, James B. Indacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for chronic obstructive pulmonary disease. Reviews. 2015, 1 (3): CD010139. PMC 6464646 . PMID 25575340. doi:10.1002/14651858.CD010139.pub2. 
  8. ^ European Public Assessment Report for Onbrez Breezhaler 互聯網檔案館存檔,存檔日期2010-01-16.
  9. ^ FDA approves Arcapta Neohaler to treat chronic obstructive pulmonary disease (新聞稿). U.S. Food and Drug Administration. 2011-07-01 [2011-07-02]. (原始內容存檔於2011-07-03). 
  10. ^ Drug Approval Package: Arcapta Neohaler (indacaterol maleate) NDA #022383. U.S. Food and Drug Administration. 13 August 2013 [14 June 2021]. (原始內容存檔於2021-04-07). 
  11. ^ Faulkner, Sarah. Sunovion, Novartis ink licensing deal for inhaled COPD drugs. Drug Delivery Business. 22 December 2016 [2024-05-23]. (原始內容存檔於2021-10-31).